以最新收盘价计算，A股平均股价为11.48元，其中股价超过100元的有80只，相比上一个交易日减少3只。 （原标题：百元股数量达80只，电子、医药生物、计算机行业占比均超10%） | 代码 简称 | 最新收盘价 | | 今日涨跌（%） | 换手率（%） | 行业 | | --- | --- | --- | --- | --- | --- | | | | （元） | | | | | 600519 贵州茅台 | | 1509.00 | -0.85 | 0.23 食品饮料 | | | 688256 寒武纪 | | 595.86 | -1.29 | 0.01 | 电子 | | 832982 锦波生物 | | 484.35 | 2.72 | 2.48 美容护理 | | | 002371 北方华创 | | 424.77 | 1.48 | 0.55 | 电子 | | 688608 恒玄科技 | | 396.03 | 1.12 | 0.02 | 电子 | | 688617 惠泰医疗 | | 392.12 | -1.11 | 0.01 医药生物 | | | 002594 比亚迪 | | 356.00 | 1.05 | 1.56 ...

Core Insights - The innovative drug sector is experiencing strong performance driven by multiple catalysts, including the approval of 11 innovative drugs by the National Medical Products Administration, showcasing the commercialization potential of pharmaceutical companies [4] - China's pharmaceutical companies are achieving breakthroughs through technological innovation and international expansion, with a significant increase in the number of innovative drugs under development, reaching 4,804 by 2024, making China the second globally after the US [4] - The government is providing comprehensive support for innovative drugs, with policies aimed at enhancing the entire value chain from research and development to payment, which is expected to improve the commercialization process for innovative drugs [4] Industry Analysis - The demand for innovative drugs is driven by an aging population and unmet medical needs in areas such as cancer and autoimmune diseases, with the elderly population expected to reach 310 million by the end of 2024, accounting for 22% of the total population [4] - The penetration rate of innovative drugs for autoimmune diseases remains low, indicating substantial market demand [4] Company-Specific Insights - **NuoSiLanDe**: An innovative biotech company with its first gene therapy drug expected to be approved by 2025, targeting new pathways and preparing for commercialization [4][5] - **KangLeWeiShi**: Focused on HPV vaccines, with significant progress in its pipeline, including a three-valent HPV vaccine expected to be approved by 2025 [4] - **DeYuan Pharmaceutical**: Specializes in chronic disease markets, with a focus on diabetes and cardiovascular diseases, and is developing a first-class innovative drug in collaboration with WuXi AppTec [4][5] - **JinBo Bio**: Leading in recombinant collagen technology with applications in skincare and medical fields, collaborating with various research institutions to advance its product offerings [7] - **HaiNeng Technology**: Aiming to replace imported scientific instruments, particularly in the chromatography sector, with plans to launch a new chromatography workstation software by 2025 [7] - **XinZhi Bio**: Focused on life science instruments, with a strategy to streamline its product offerings and enhance application scenarios [7] - **FeiYi Pharmaceutical**: Engaged in CDMO business, providing services to major pharmaceutical companies in Japan and South Korea, with plans to expand into cardiovascular drug production [7]

Core Viewpoint - The recent controversy surrounding hyaluronic acid and recombinant collagen products has led to significant scrutiny and volatility for leading companies in the medical beauty biotechnology sector, including Huaxi Biological, Juzhi Biological, and Jinbo Biological [2][11]. Group 1: Controversy and Market Reactions - Huaxi Biological publicly criticized brokerage reports for promoting the "hyaluronic acid is outdated" narrative, suggesting that the recombinant collagen concept is being overly hyped [3][11]. - Juzhi Biological faced public backlash due to a report indicating that its product "Kefumei" contained only 0.0177% recombinant collagen, below the legal threshold of 0.1% [4][11]. - Jinbo Biological's stock price was affected by the overall negative sentiment in the collagen sector, experiencing a significant drop of 17.23% from its peak [5][7]. Group 2: Financial Performance - Huaxi Biological reported its worst performance since going public in 2024, with revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [9][10]. - Juzhi Biological achieved a revenue of 5.539 billion yuan in 2024, a year-on-year growth of 57.2%, but its core product's growth rate has been declining for four consecutive years [9][10]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, but its growth rate has also shown signs of slowing down [10]. Group 3: Industry Dynamics - The ongoing "ingredient dispute" highlights the competition between hyaluronic acid and recombinant collagen technologies, with Huaxi Biological emphasizing the scientific value of hyaluronic acid [11][13]. - The controversy may intensify competition in technology development, market promotion, and brand building within the medical beauty industry, pushing for more emphasis on product efficacy and scientific validation [13].

Market Overview - On May 29, the total trading volume of stocks on the Beijing Stock Exchange reached 1.409 billion shares, with a total transaction value of 28.186 billion yuan, an increase of 4.064 billion yuan compared to the previous trading day [1] - A total of 246 stocks closed higher, accounting for 92.83% of the tradable stocks, with notable gainers including Xinan Clean (up 16.95%), Yunxingyu (up 16.49%), and Tianming Technology (up 14.98%) [1] Trading Activity - 90 stocks had transaction values exceeding 10 million yuan, with Jinbo Biological, Airong Software, and Guohang Ocean leading at 777.1 million yuan, 684.1 million yuan, and 558.4 million yuan respectively [1] - The trading activity showed that 53 stocks had a turnover rate exceeding 10%, with 10 stocks exceeding 20%. The highest turnover rates were recorded for Shengye Electric (48.87%), Jike Co. (32.00%), and Ruiqi Intelligent Manufacturing (31.07%) [1] Notable Stocks - Jinbo Biological closed at 446.50 yuan with a decline of 3.56% and a turnover rate of 3.74% [1] - Airong Software closed at 60.71 yuan, up 7.85% with a turnover rate of 9.72% [1] - Guohang Ocean closed at 10.51 yuan, up 3.85% with a turnover rate of 18.64% [1] - Yunxingyu closed at 17.94 yuan, up 16.49% with a turnover rate of 10.40% [1] - Xinan Clean closed at 6.14 yuan, up 16.95% with a turnover rate of 28.93% [1] - Shengye Electric closed at 44.88 yuan, up 13.56% with a turnover rate of 48.87% [1] Summary of Performance - The overall market performance indicated strong bullish sentiment with a significant number of stocks experiencing gains, reflecting positive investor sentiment and trading activity on the Beijing Stock Exchange [1]

Group 1 - The average stock price of A-shares is 11.42 yuan, with 85 stocks priced over 100 yuan, a decrease of 5 from the previous trading day [1] - The Shanghai Composite Index closed at 3340.69 points, down 0.18%, while stocks priced over 100 yuan had an average decline of 1.04%, underperforming the index by 0.86 percentage points [1] - The highest closing price among stocks over 100 yuan is Kweichow Moutai at 1543.90 yuan, down 0.43% [1] Group 2 - In the past month, stocks priced over 100 yuan have averaged an increase of 0.81%, while the Shanghai Composite Index rose by 1.38% [2] - The top gainers among these stocks include United Chemical, S-Ling Co., and Guoguang Electric, with increases of 61.49%, 48.57%, and 45.25% respectively [2] - Year-to-date, the average increase for stocks over 100 yuan is 21.92%, outperforming the Shanghai Composite Index's increase of 22.25% [2] Group 3 - By industry classification, the electronics sector has the highest concentration with 26 stocks, accounting for 30.59% of the stocks priced over 100 yuan [2] - The computer and pharmaceutical sectors each have 10 stocks, representing 11.76% of the total [2] Group 4 - Among the stocks priced over 100 yuan, 25 are from the main board, 22 from the ChiNext, 3 from the Beijing Stock Exchange, and 35 from the Sci-Tech Innovation Board, with the latter making up 41.18% of the total [3]

Core Viewpoint - Taiyuan City is focusing on industrial transformation and the cultivation of strategic emerging industries, enhancing innovation and establishing a green manufacturing system to drive high-quality economic development [1][31]. Group 1: Macroeconomic Analysis - Taiyuan's GDP for 2024 is projected to be CNY 541.887 billion, with a growth rate of 1.2%. The primary, secondary, and tertiary industries contribute CNY 4.785 billion, CNY 166.671 billion, and CNY 370.431 billion respectively, with the tertiary sector growing by 1.6% [2][4]. - The proportion of strategic emerging industries in Taiyuan's industrial output is increasing, with a 2024 forecast showing a 37.3% contribution to the total industrial output, up 1.4 percentage points from the previous year [4]. Group 2: Investment Trends - Fixed asset investment in Taiyuan is expected to grow by 0.5% in 2024, with 136 ongoing projects valued over CNY 1 billion, representing 35.9% of total investment [6]. - Industrial investment is projected to account for 27.7% of total investment, with a significant increase of 24.7% year-on-year [6]. Group 3: Industrial Structure - Taiyuan is constructing a modern industrial system centered around the "1233" key industrial chain system, which includes nine major industrial chains contributing approximately 70% of the city's industrial output [10][31]. - The "1233" system focuses on high-end metal materials, advanced carbon-based materials, and advanced biological materials, among others, with 118 key enterprises involved [10][31]. Group 4: Innovation and R&D - In 2023, Taiyuan's R&D expenditure reached CNY 12.79 billion, ranking first in Shanxi Province, indicating a strong focus on innovation [8]. - The city is implementing four major projects to enhance innovation capabilities, including optimizing the innovation ecosystem and promoting the transformation of innovative results [8]. Group 5: Key Industries - The high-end metal materials industry is a pillar of Taiyuan's economy, with significant products including special steel and new magnesium alloys, generating CNY 118.3 billion in revenue in 2023 [19][20]. - The carbon-based materials industry is leveraging local coal resources and advanced research capabilities, with a focus on both traditional and cutting-edge carbon materials [25][27]. - The advanced biological materials and biopharmaceutical industry is developing rapidly, focusing on bio-based new materials and recombinant human collagen protein [29]. Group 6: Policy Framework - Taiyuan has introduced several policies to support high-quality development, including plans for digital transformation and the establishment of advanced manufacturing bases [16][18]. - The city aims to achieve significant results in industrial high-quality development by 2025, enhancing its competitive advantages [16].

山西锦波生物医药股份有限公司 章 程 二〇二五年五月 山西锦波生物医药股份有限公司章程 山西锦波生物医药股份有限公司章程 第一章 总则 第一条 为维护山西锦波生物医药股份有限公司（以下简称"公司"或"本 公司"）、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简 称《证券法》）、《北京证券交易所股票上市规则（试行）》（以下简称《上市 规则》）和其他有关法律法规、行政规章、规范性文件的规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司由太原锦波生物医药科技有限公司依法整体变更设立。在山西省太原市 工商行政管理局注册登记，取得营业执照，统一社会信用代码为： 91140100672338346F。 第三条 公司全部资产分为等额股份，股东以其认购的股份为限对公司承担 责任，公司以其全部资产对公司的债务承担责任。 第四条 本章程自生效之日起，即成为规范公司的组织与行为、公司与股东、 股东与股东之间权利义务关系的具有法律约束力的文件，对公司、股东、董事、 监事、高级管理人员具有法律约束力的法律文件。依 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-064 山西锦波生物医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 21 日 2.会议召开地点：山西综改示范区太原唐槐园区锦波街 18 号公司九楼会议 室 3.会议召开方式：现场投票及网络投票 4.会议召集人：公司董事会 5.会议主持人：董事长杨霞女士 6.召开情况合法合规的说明： 本次股东会的召集、召开程序符合有关法律、行政法规、部门规章、规范性 文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履行其他 必要的程序。 （二）会议出席情况 同意股数 53,902,177 股，占本次股东会有表决权股份总数的 100%；反对股 数 0 股，占本次股东会有表决权股份总数的 100%；弃权股数 0 股，占本次股东 会有表决权股份总数的 100%。 2.回避表决情况 出席和授权出席本次股东会的股东共 33 ...

G E Y U A N 格 远 律 师 事 务 所 Law Firm 关于山西锦波生物医药股份有限公司 2024 年年度股东会的 法律意见书 山西格远律师事务所 )二五年五 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2024 年年度股东会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法(2019年修订)》(以下简称"《证券法》")《中 华人民共和国公司法(2023年修正)》(以下简称"《公司法》")《北京证券交易 所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、法规和其他 有关规范性文件的要求,山西格远律师事务所(以下简称"本所")接受山西锦 波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委托,指派律 师参加公司 2024年年度股东会(以下简称"本次股东会"或"本次会议")。 均真实有效:所有相关自然人均具有完全民事行为能力;锦波生物相关工作人员 口头介绍的情况均是真实、准确、完整的。本所律师依法对出具本《法律意见书》 所依据的文件资料的真实性、准确性、完整性进行了核查和验证。核查和验证时, 本所律师对与法律相关的事项履行法律专业人士特别的注意义 ...

Market Overview - On May 23, the total trading volume of stocks on the Beijing Stock Exchange reached 1.269 billion shares, with a total transaction value of 27.181 billion yuan, a decrease of 10.005 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 57 stocks closed higher, accounting for 21.43% of the total, with notable gainers including Chenguang Medical, Changfu Co., and Senxuan Pharmaceutical, which rose by 14.96%, 10.12%, and 9.73% respectively [1] - Conversely, 208 stocks closed lower, with the largest declines seen in Kexin New Materials, Shengnan Technology, and Air China Ocean, which fell by 9.04%, 8.54%, and 7.89% respectively [1] Trading Activity - A total of 87 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Jinbo Biological, Changfu Co., and Wuxin Tunnel Equipment, at 813 million yuan, 597 million yuan, and 517 million yuan respectively [1] - In terms of trading activity, 48 stocks had a turnover rate exceeding 10%, with 8 stocks exceeding 20%. Additionally, 94 stocks had turnover rates between 5% and 10%, while 122 stocks had turnover rates between 1% and 5% [1] - The stocks with the highest turnover rates included Ningxin New Materials, Chenguang Medical, and Changfu Co., with turnover rates of 33.42%, 32.11%, and 31.21% respectively [1] Stock Performance - The closing prices and performance of notable stocks included: - Jinbo Biological: Closing price of 497.70 yuan, up 0.85%, turnover rate of 3.54%, transaction value of 812.56 million yuan [1] - Changfu Co.: Closing price of 45.90 yuan, up 10.12%, turnover rate of 31.21%, transaction value of 597.47 million yuan [1] - Wuxin Tunnel Equipment: Closing price of 41.27 yuan, down 7.28%, turnover rate of 14.02%, transaction value of 516.61 million yuan [1] - Chenguang Medical: Closing price of 21.90 yuan, up 14.96%, turnover rate of 32.11%, transaction value of 473.16 million yuan [1] - Air China Ocean: Closing price of 10.04 yuan, down 7.89%, turnover rate of 15.90%, transaction value of 473.14 million yuan [1]